Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK536692PMID: 30694624
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 2055491-00-2
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of tagraxofusp during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during tagraxofusp therapy and for 1 week after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Tagraxofusp
CAS Registry Number
2055491-00-2
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).[Expert Opin Biol Ther. 2020]Review Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).Alfayez M, Konopleva M, Pemmaraju N. Expert Opin Biol Ther. 2020 Feb; 20(2):115-123. Epub 2019 Dec 17.
- Review Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.[Leuk Lymphoma. 2024]Review Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.Pemmaraju N, Madanat YF, Rizzieri D, Fazal S, Rampal R, Mannis G, Wang ES, Foran J, Lane AA. Leuk Lymphoma. 2024 May; 65(5):548-559. Epub 2024 Feb 23.
- Review Binimetinib.[Drugs and Lactation Database (...]Review Binimetinib.. Drugs and Lactation Database (LactMed®). 2006
- Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.[Blood Adv. 2020]Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.Pemmaraju N, Konopleva M. Blood Adv. 2020 Aug 25; 4(16):4020-4027.
- Review Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.[Minerva Med. 2020]Review Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.Cangini D, Silimbani P, Cafaro A, Giannini MB, Masini C, Ghelli Luserna Di Rorà A, Simonetti G, Martinelli G, Cerchione C. Minerva Med. 2020 Oct; 111(5):467-477. Epub 2020 Sep 21.
- Tagraxofusp - Drugs and Lactation Database (LactMed®)Tagraxofusp - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...